Tracking lives: does a new diabetes drug make daily life easier?
NCT ID NCT07260110
Summary
This study aims to understand how the drug teplizumab affects the daily lives and health of people with early-stage type 1 diabetes. It will follow 550 people in the U.S. for five years, comparing those who received the drug to those who did not. The main goal is to measure changes in quality of life, anxiety, and the burden of managing the condition.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Investigational Site
RECRUITINGSan Francisco, California, 94107, United States
Conditions
Explore the condition pages connected to this study.